Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07063407Phase 1Not Yet Recruiting

Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer

Role: lead

NCT05263479Phase 1Recruiting

A Study of HS-20089 in Patients With Advanced Solid Tumors

Role: lead

NCT05276609Phase 1Unknown

ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors

Role: lead

NCT04940845Phase 1Unknown

Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults

Role: lead

All 4 trials loaded